Recursion Pharmaceuticals Stock Performance
| RXRX Stock | USD 4.47 0.13 2.83% |
The company holds a Beta of 0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Recursion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Recursion Pharmaceuticals is expected to be smaller as well. At this point, Recursion Pharmaceuticals has a negative expected return of -0.26%. Please make sure to check Recursion Pharmaceuticals' skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Recursion Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Recursion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.36) | Five Day Return (11.84) | Year To Date Return 2.86 | Ten Year Return (76.00) | All Time Return (76.00) |
1 | Disposition of 40390 shares by Christopher Gibson of Recursion Pharmaceuticals at 4.14 subject to Rule 16b-3 | 11/17/2025 |
2 | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence Stock | 11/24/2025 |
3 | Disposition of 2271 shares by Ben Taylor of Recursion Pharmaceuticals at 4.03 subject to Rule 16b-3 | 11/25/2025 |
4 | Disposition of 220000 shares by Blake Borgeson of Recursion Pharmaceuticals at 4.37 subject to Rule 16b-3 | 12/02/2025 |
5 | Positive Phase 1b2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis at 25 W... | 12/08/2025 |
6 | Disposition of 7057 shares by Ben Taylor of Recursion Pharmaceuticals at 4.33 subject to Rule 16b-3 | 12/15/2025 |
7 | Disposition of 124403 shares by Najat Khan of Recursion Pharmaceuticals at 4.4098 subject to Rule 16b-3 | 12/22/2025 |
8 | JPMorgan Boosts Rating on Recursion Pharmaceuticals Amid AI-Driven Drug Pipeline | 01/02/2026 |
9 | Recursion Pharmaceuticals Assessing Valuation After New Activist Investor Filings With the SEC | 01/05/2026 |
10 | Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference | 01/06/2026 |
11 | Recursion Pharmaceuticals Stock Sinks As Market Gains What You Should Know | 01/08/2026 |
12 | Why Recursion Pharmaceuticals stock is up today a new JPM deck put cash runway back in focus - TechStock | 01/12/2026 |
13 | Assessing Recursion Pharmaceuticals Valuation After JP Morgan Update And REC-4881 Clinical Milestones | 01/16/2026 |
14 | Disposition of 40000 shares by Christopher Gibson of Recursion Pharmaceuticals at 4.47 subject to Rule 16b-3 | 01/20/2026 |
15 | Is Recursion Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage | 01/23/2026 |
| Begin Period Cash Flow | 401.4 M | |
| Total Cashflows From Investing Activities | 260.1 M |
Recursion | Build AI portfolio with Recursion Stock |
Recursion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 552.00 in Recursion Pharmaceuticals on October 31, 2025 and sell it today you would lose (105.00) from holding Recursion Pharmaceuticals or give up 19.02% of portfolio value over 90 days. Recursion Pharmaceuticals is currently does not generate positive expected returns and assumes 4.1976% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Recursion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Recursion Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Recursion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.47 | 90 days | 4.47 | about 63.79 |
Based on a normal probability distribution, the odds of Recursion Pharmaceuticals to move above the current price in 90 days from now is about 63.79 (This Recursion Pharmaceuticals probability density function shows the probability of Recursion Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Recursion Pharmaceuticals has a beta of 0.54 indicating as returns on the market go up, Recursion Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Recursion Pharmaceuticals will be expected to be much smaller as well. Additionally Recursion Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Recursion Pharmaceuticals Price Density |
| Price |
Predictive Modules for Recursion Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Recursion Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Recursion Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Recursion Pharmaceuticals is not an exception. The market had few large corrections towards the Recursion Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Recursion Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Recursion Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 0.54 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | -0.08 |
Recursion Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Recursion Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Recursion Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Recursion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Recursion Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 58.84 M. Net Loss for the year was (463.66 M) with loss before overhead, payroll, taxes, and interest of (503.45 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is Recursion Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage |
Recursion Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Recursion Stock often depends not only on the future outlook of the current and potential Recursion Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Recursion Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 274.2 M | |
| Cash And Short Term Investments | 594.4 M |
Recursion Pharmaceuticals Fundamentals Growth
Recursion Stock prices reflect investors' perceptions of the future prospects and financial health of Recursion Pharmaceuticals, and Recursion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Recursion Stock performance.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (33.28) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 514.19 M | ||||
| Price To Book | 2.22 X | ||||
| Price To Sales | 53.33 X | ||||
| Revenue | 58.84 M | ||||
| Gross Profit | (503.45 M) | ||||
| EBITDA | (426.72 M) | ||||
| Net Income | (463.66 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 108.49 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (359.17 M) | ||||
| Earnings Per Share | (1.84) X | ||||
| Market Capitalization | 2.33 B | ||||
| Total Asset | 1.45 B | ||||
| Retained Earnings | (1.43 B) | ||||
| Working Capital | 526.8 M | ||||
About Recursion Pharmaceuticals Performance
Evaluating Recursion Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Recursion Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Recursion Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.52) | (0.49) |
Things to note about Recursion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Recursion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Recursion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Recursion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Recursion Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 58.84 M. Net Loss for the year was (463.66 M) with loss before overhead, payroll, taxes, and interest of (503.45 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is Recursion Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage |
- Analyzing Recursion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Recursion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Recursion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Recursion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Recursion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Recursion Pharmaceuticals' stock. These opinions can provide insight into Recursion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.